Jeanette Mucha is a Co-founder and CEO of SciBac Inc. She is a microbiologist and immunologist with fourteen years' corporate R&D experience. She is the inventor of SciBac's platform technology, MERGE, which allows SciBac to produce better bugs as drugs. She has additional patents in the areas of strain improvement and immunology. Jeanette started SciBac in her Silicon Valley garage in 2015 as the Chief Science Officer and took over as SciBac's CEO in March 2017. Since then, she has secured $1.85M including investments from Breakout Labs and iSelect Fund while also securing revenue from industrial contracts including Novozymes. She helped negotiate a $3.86M non-dilutive grant from CARB-X which will get SciBac's first therapeutic for C diff into the clinic. She has a B.S. in Biology from the University of Miami. Jeanette is also an 18-time (soon to be 19) Ironman distance triathlon finisher, including the 2009 World Championship. Her strategic vision for SciBac is to help eradicate antibiotic resistant disease in the microbiome and then tackle more complicated modern-day diseases like autism, obesity and auto-immune disorders which all have connections to changes in the microbiome.